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Introduction
Phylloides breast tumors are characterized by prolife-
ration of both epithelial and mesenchymal cells. Their in-
cidence in the population affected by breast cancer is 
< 1%. The age range at higher risk is between 35 and
45 years (1, 2), mostly among Latin American women. 
Because of their very low incidence and for the va-
riety of surgical options, we report a case of giant phyl-
loides tumor in a 47 year-old patient. 
Case report
A 47 year-old woman come to our attention for the presence
of a huge mass involving her right breast. The patient referred the
presence of a lump of 3-4 cm since some months. Because a for-
mer malignant neoplasm in her family, she, feargue, refused to ha-
ve any exam until March 2006 when she came to our attention for
a rapid increase of the neoplasm with skin ulceration.
A clinical examination showed the presence of a 15 cm, hard,
moderately painful at light touch, mobile, ulcerated mass in the ri-
ght breast. No sovraclavear or cervical lesions were detectable on
physical examination (Fig. 1).
Laboratory test documented only a mild anemia (Hb 10,9
g/dL). Fine needle aspiration biopsy showed stromal fibrosis with
epithelial hyperplasia and some calcifications.
For the rapid local progression of the mass on April  2006 we
performed right mastectomy. A solid mass of 25 cm with an arbo-
riform ulceration  of the skin was removed (Fig. 2).
The postoperative course was uneventful and the patient was
discharged after 36 hours from surgery. 
Histology documented the complete substitution of the gland,
which sized  28x21x15 cm, by an heterogeneous neoplastic tissue,
constituted by central hemorrhagic areas and cystic degeneration,
high stromal component, pleiomorphism and high mitotic index
(17 mitosis x 10 HPF). A skin ulceration of 6x7 cm was present.
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The incidence of phylloides breast tumors is less than 1% in the
population affected by breast cancers. The age at higher risk is between
35 and 45 years. These neoplasms are characterized by a proliferation
of mesenchimal and epithelial cells. 
We present a rare case of giant malignant phylloides tumor
(28x21x15 cm) with a complet substitution of the gland. The clinical
presentation of phylloides tumors is heterogenous; the surgical treat-
ment is a conservative one of the gland if the neoplastic lesion size is
less than 5 cm with a free margin of 1 cm and a mastectomy if the dia-
meter of lesion is more than 5 cm. Complementary therapies still re-
main controversial.
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Presentiamo un raro caso di tumore filloide gigante (28x21x15
cm) con completa sostituzione della ghiandola. La presentazione clini-
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These findings were suggestive of phylloides malignant tumor. Re-
section margins were free from disease.
Discussion
Phylloides tumors are mesenchimal neoplasms of
the breast. They were described for the first time by
Müller in 1838 (3).
Their clinical presentation is heterogenous for sha-
pe and sizes. Surgical treatment depends on tumor size.
The conservative treatment depend on resection mar-
gins also: if they are free from disease for at least 1 cm,
local recurrence rate, which is usually 13-15%, decrea-
ses significantly.
In the 20% of cases phylloides tumors present with
clinically limphoadenopaties but only 5% of nodes is
actually involved by the disease (3, 4).
Some authors studied the correlation between
Ki67 and hystologic grade while others focused on
p53, c-kit and growth factor receptors. All of these fac-
tors were related to tumor growth but up to date no
markers has been predictive of disease. Genetical stu-
dies highlighted how chromosomes 1, 3, 12 and 18
present rearrangements and modifications, expecially
compared to fibroadenomas (5).
For phylloides tumors larger than 5 cm a mastec-
tomy is advisable while for smaller tumors is advisable
a resection with free margin of 1 cm or more. If the re-
section does not allow a free margin of at least 1 cm,
some authors advice radiotherapy wich improves sur-
vival and reduces local recurrence. A common agree-
ment on chemotherapic protocols for this kind of neo-
plasms has not been achieved yet (4). 
A study on 48 women with malignant phylloides
tumors showed the presence of distant metastasis in
37% of patients, local recurrence before the evidence
of distant metastasis in one third and a mean disease
free survival of 60.5 months (4). Distant metastasis,
which are mainly due to hematic diffusion, occur mo-
st frequently to lungs, pleurae and bones. The 5 year
survival rate is 90% (1). 
Conclusions
The surgical treatment of breast phylloides tumors
is mastectomy for lesions > 5 cm, and conservative
therapy, with free margins more than 1 cm, for  5 cm
ones. Complementary therapies, such as chemothe-
rapy, still remain controversial.
Fig. 1 - Breast lesion before surgical procedure.
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Fig. 2 - Surgical mass. 
